Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 12/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 1.00 |
| ▸ | SLC10A2 | Q12908 | 3/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | ENPP2 | Q13822 | 2/20 | 1.00 |
| ▸ | PLA2G1B | P04054 | 1/20 | 1.00 |
| ▸ | SLC10A1 | Q14973 | 6/20 | 0.89 |
| ▸ | VDR | P11473 | 1/20 | 0.79 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taurochenodeoxycholate SCHEMBL19360984 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 | |
| Taurochenodeoxycholate SCHEMBL17703645 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 | |
| Taurursodiol SCHEMBL40764 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 | |
| Taurochenodeoxycholate SCHEMBL24001493 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 | |
| Taurochenodeoxycholate SCHEMBL20204256 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 | |
| Taurochenodeoxycholate SCHEMBL24435723 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 | |
| Taurochenodeoxycholate SCHEMBL56780 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 | |
| Taurochenodeoxycholate SCHEMBL24015433 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 | |
| Taurochenodeoxycholate SCHEMBL56779 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 | |
| Taurochenodeoxycholate SCHEMBL12917602 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2ABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2021-10-21 | — | — | US | claimed |
| US-20230277491-A1 | PHARMACEUTICAL COMBINATION COMPRISING GLYCOLIC ACID AND L-ALANINE | PAN MONTOJO FRANCISCO (DE) | 2023-09-07 | — | — | US | disclosed |
| WO-2023081658-A2 | HIGH PURITY NON-ANIMAL DERIVED TUDCA | SANDHILL ONE, LLC (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230040386-A1 | URSODEOXYCHOLIC ACID-CONTAINING AGENT FOR TREATING OR PREVENTING PRESBYOPIA | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2023-02-09 | — | — | US | disclosed |
| US-11419880-B2 | Ursodeoxycholic acid-containing agent for treating or preventing presbyopia | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2022-08-23 | — | — | US | disclosed |
| US-11298314-B2 | Injectable composition for localized fat reduction without pain, edema, and side effects, and method for preparing same | AMI PHARM CO., LTD. (KR) | 2022-04-12 | — | — | US | disclosed |
| CN-113874520-A | Intestinal biomarkers for gut health in poultry | 杜邦营养生物科学有限公司 | 2021-12-31 | — | — | CN | disclosed |
| EP-3900728-A1 | URSODEOXYCHOLIC ACID-CONTAINING AGENT FOR TREATING OR PREVENTING PRESBYOPIA | Santen Pharmaceutical Co., Ltd. (JP) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020129964-A1 | URSODEOXYCHOLIC ACID-CONTAINING AGENT FOR TREATING OR PREVENTING PRESBYOPIA | 参天製薬株式会社 | 2020-06-25 | — | — | WO | disclosed |
| CN-105784854-B | Method for detecting related substances in tauroursodeoxycholic acid | 重庆药友制药有限责任公司 | 2020-06-16 | — | — | CN | disclosed |
| US-20190201328-A1 | INJECTABLE COMPOSITION FOR LOCALIZED FAT REDUCTION WITHOUT PAIN, EDEMA, AND SIDE EFFECTS, AND METHOD FOR PREPARING SAME | AMI PHARM CO., LTD. (KR) | 2019-07-04 | — | — | US | disclosed |
| EP-3479827-A1 | INJECTABLE COMPOSITION FOR LOCALIZED FAT REDUCTION WITHOUT PAIN, EDEMA, AND SIDE EFFECTS, AND METHOD FOR PREPARING SAME | AMI Pharm Co., Ltd. (KR) | 2019-05-08 | — | — | EP | disclosed |
| EP-3335730-A1 | COMPOUNDS FOR TREATING X-LINKED ADRENOLEUKODYSTROPHY | Fundació Institut de Recerca Biomédica de Bellvitge (IDIBELL) (ES) | 2018-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230040386-A1 | URSODEOXYCHOLIC ACID-CONTAINING AGENT FOR TREATING OR PREVENTING PRESBYOPIA | NR1H4, SLC10A1, HMGCR | GPBAR1 7/4885NR1H4 1/4885SLC10A2 4/4885 |
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LIPE, GPR119, FABP4 | GPBAR1 291/4885NR1H4 679/4885SLC10A2 3157/4885 |
| US-20190201328-A1 | INJECTABLE COMPOSITION FOR LOCALIZED FAT REDUCTION WITHOUT PAIN, EDEMA, AND SIDE EFFECTS, AND METHOD FOR PREPARING SAME | GYS1, FABP4, ACACA | GPBAR1 26/4885NR1H4 42/4885SLC10A2 21/4885 |
| US-11298314-B2 | Injectable composition for localized fat reduction without pain, edema, and side effects, and method for preparing same | GYS1, FABP4, ACACA | GPBAR1 26/4885NR1H4 42/4885SLC10A2 21/4885 |
| US-11419880-B2 | Ursodeoxycholic acid-containing agent for treating or preventing presbyopia | NR1H4, SLC10A1, HMGCR | GPBAR1 7/4885NR1H4 1/4885SLC10A2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.